FDA advisory panel recommends approval of Bayer's lung drug
Aug 6 (Reuters) - Bayer AG's experimental drug to treat two types of pulmonary hypertension should be approved, an advisory panel to the U.S. Food and Drug Administration said on Tuesday.
The panel voted 11-0 that the FDA should approve the drug, riociguat, which in clinical trials extended the distance patients could walk during a six-minute test.
The FDA is not obliged to follow the recommendation of its advisory panel, but typically does so. If approved, the drug would be sold under the brand name Adempas.
(Reporting by Toni Clarke in Washington; Editing by John Wallace and Gerald E. McCormick)
- iPhone comes out of a 'bygone era', reviewers hail bigger handset
- Scots' support for independence lags on eve of referendum |
- Boeing, SpaceX win contracts to build 'space taxis' for NASA
- Fed could hint on rate-hike plans as it prepares for policy turn
- Polls show Scottish opponents of independence with slight lead ahead of vote |